Skip to content

Oral Penicillin Challenge and Allergy De-labeling in Children

Oral Penicillin Challenge and Allergy De-labeling in the Phoenix Children's Hospital Emergency Department

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05563610
Enrollment
31
Registered
2022-10-03
Start date
2022-09-26
Completion date
2024-06-12
Last updated
2024-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Penicillin Allergy

Keywords

penicillin, anaphylaxis, allergy, oral challenge, amoxicillin, pediatric, emergency department

Brief summary

The primary purpose of this study is to investigate the portion of penicillin allergy labels that are not true allergies using oral amoxicillin challenges among pediatric patients. The secondary purpose is to evaluate the safety and feasibility of administering oral penicillin allergy challenges in the Pediatric Emergency Department.

Interventions

Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not

Sponsors

Phoenix Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Patients in the pediatric emergency department who are 2-17 yo and labeled as penicillin-allergic (including amoxicillin or other penicillin allergies) 2. Patients at low risk of anaphylaxis as determined by the study questionnaire 3. Patients who would normally be prescribed amoxicillin, amoxicillin-clavulanate or another penicillin for their current bacterial infection, including otitis media, Group A Streptococcal pharyngitis, pneumonia. sinusitis, dog and cat bite wounds, regimens for Helicobacter pylori eradication, or other acute infections deemed susceptible. 4. Patients who are interested in participating 5. Patients who have an acceptable surrogate to give consent on the subject's behalf 6. Patients whose surrogate (parent/caregiver) speaks English or Spanish

Exclusion criteria

1. Patients who are uninterested in participating, or their parents/caregivers are not interested in having them participate 2. Patients who have multiple drug allergies

Design outcomes

Primary

MeasureTime frameDescription
True Penicillin Allergies24 hours after amoxicillin oral challengePercentage of study patients presenting to the pediatric ED who received the amoxicillin oral challenge who demonstrated a true IgE-mediated allergic reaction

Secondary

MeasureTime frameDescription
Amoxicillin Oral Challenge Safety - High-Risk Reactions24 hours after amoxicillin oral challengePercentage of high-risk penicillin allergic reactions
Amoxicillin Oral Challenge Safety - Admissions24 hours after amoxicillin oral challengePercentage of admissions from the pediatric ED in patients experiencing high-risk penicillin allergic reactions
Amoxicillin Oral Challenge Safety - Re-admissions24 hours after amoxicillin oral challengePercentage of re-admissions from home after discharge from the pediatric ED in patients experiencing high-risk penicillin allergic reactions
Amoxicillin Oral Challenge Safety - Deaths24 hours after amoxicillin oral challengePercentage of deaths in patients experiencing high-risk penicillin allergic reactions
Amoxicillin Oral Challenge Feasibility24 hours after amoxicillin oral challengeAverage hospital length of stay in the pediatric ED for patients receiving the amoxicillin oral challenge relative to the non-treatment group

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026